Potassium Citrate 1080 mg/5 mL Solution
Natural health product licensed in Canada
- Licence holder
- BIOVANTEK
- NPN or DIN-HM
- 80071797
- Status
- Inactive licence
- Licence date
- 8 August 2016
- Revision date
- 17 May 2022
- Form
- Liquide oral, solution
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Potassium Source : Citrate de potassium monohydraté | 78 mg/ml | Not calculated |
Non-medicinal ingredients
Benzoate de sodium, Sorbate de potassium, Eau, Sorbitol, Glycérol, Saveur, D-Fructose, Aspartame
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | minimum: 5 millilitre ; maximum: 12.5 millilitre | minimum: 2 Tous les jours ; maximum: 4 Tous les jours |
Uses authorised in Canada
Treatment or prevention of hypokalemia (potassium depletion) which does not result from dietary deficiency.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
To be taken only on the advice of a physician. Where impaired renal function exists, the use of potassium supplements must be monitored closely. The use of potassium supplements with sparing diuretics (spironolactone, triamterene, amiloride) may lead to hyperkalemia. Not to be used following vigorous exercise or acute dehydration (unless administered with an appropriate balance of other mineral salts, e.g. sodium). Do not use if you have adrenal insufficiency or uncontrolled diabetes mellitus. Do not use if you are taking prescription medications especially those which increase serum potassium such as potassium-spanning diuretics or angiotensin converting enzyme (ACE) inhibitors. Do not use with other potassium-containing supplements or with potassium-containing salt substitutes. Consult with a health care practitioner prior to use if you have a kidney or heart condition. Discontinue use and consult a health care practitioner immediately if you experience numbness of the extremities, muscle weakness, paralysis, cardiac arrhythmias, low blood pressure, or confusion. Consult a health care practitioner prior to use if you are pregnant or breastfeeding.
Source
Official Health Canada record, licence 80071797
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2022. Photograph the packaging to check whether it has changed. Photograph the packaging